A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
← catalyst calendarNCT07614776 · readout in 345 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
304estimated
Sites
51
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-27 | actual | When the study began enrolling |
| Primary completion | 2027-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-12 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neovascular Age-related Macular Degeneration
- nAMD
Interventions
- Drug: ABP 938 8 mg
- Drug: Aflibercept (US) 8 mg — also filed as EYLEA HD
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
measured Baseline and Week 12
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed